Home > Haematology > ASH 2021 > Multiple Myeloma > TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

Presented By
Dr Ajai Chari, Mount Sinai School of Medicine, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 1, TRIMM-2
Talquetamab plus daratumumab demonstrated durable and deep responses in heavily pre-treated patients with refractory multiple myeloma (MM) in the phase 1b TRIMM-2 trial. The combination regimen was tolerable and did not show overlapping toxicity. This novel dual therapy is therefore a promising option for the treatment of patients with MM [1]. Daratumumab is a human monoclonal antibody targeting CD38, and talquetamab is a first-in-class T cell-redirecting antibody, targeting GPRC5D and CD3 receptors, explained Dr Ajai Chari (Mount Sinai School of Medicine, NY, USA). The multicentre, open-label, phase 1b TRIMM-2 trial (NCT04108195) investigated the safety and efficacy of a combination regimen of daratumumab (subcutaneous, as per label) plus talquetamab (subcutaneous, in 3 possible regimens: 400 μg/kg, every 2 weeks; 400 μg/kg, every week; or 800 μg/...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on